In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available
2024年7月31日 - 10:05PM
ビジネスワイヤ(英語)
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has released its latest industry report, Oesophageal
Cancer — Global Clinical Trial Landscape.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240729339816/en/
This detailed analysis focuses on the extensive research and
innovative treatments being developed to combat oesophageal cancer
(OC), the seventh leading cause of cancer mortality worldwide, and
the 11th most diagnosed cancer globally, with Asia accounting for
nearly 70% of cases. Other areas of the report detail the research
pipeline for OC, highlighting significant advancements in
treatments aimed at improving patient outcomes as well as providing
a robust analysis of the funding landscape from both public and
private sources, which is currently led by entities based in China
and the USA with approximately $5B USD in investment across those
two nations.
The Novotech research analyst team provides these expert reports
monthly, highlighting key metrics on the current status of specific
diseases and outlining future trends that may impact the
development of treatments. This is provided completely free of
charge.
Key takeaways from the report:
Global Clinical Trial Activity:
- Since 2019, over 1,530 clinical trials for OC have been
initiated globally, with the Asia-Pacific region (49%), North
America (28%), and Europe (18%) leading the research efforts.
- Countries such as China, South Korea, Japan, and the USA are at
the forefront of trial activities.
Rising Incidence:
- OC is the 11th most diagnosed cancer globally, with
approximately 511,000 new cases and 445,400 deaths in 2022.
- By 2050, the annual incidence is projected to rise to 923,000
new cases, an 80.5% increase.
Innovative Treatment Approaches:
- The treatment landscape is shifting towards personalized
medicine, with systemic therapies based on disease stage and
molecular markers being recommended by the 2024 NCCN and 2022 ESMO
Guidelines.
- The development pipeline is robust, with over 90 drugs in
progress, including numerous Phase III trials focusing on diverse
mechanisms of action.
Funding and Investment:
- Significant investment has been channeled into OC research,
with China leading with $2.9 billion USD and the USA following with
$2.1 billion USD.
- Other notable contributors include Switzerland, Singapore,
Canada, and Japan.
Market Leaders:
- The report identifies key players in the OC treatment market,
including Advanz Pharma Corp. Ltd, BeiGene Ltd., InnoKeys Pte.
Ltd., and Simcere Pharmaceutical Group Ltd.
Strategic Insights:
- The report includes a SWOT analysis, demonstrating the
effectiveness of current treatments in managing symptoms and
improving quality of life, while also identifying areas where
emerging techniques may offer improvements.
Download the report here
About Novotech
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit
here
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729339816/en/
Media Contact Toyna Chin mediacontact@novotech-cro.com
USA: +1 415 364 8135